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Abstract 
Background:To determine the frequency of 
metabolic syndrome (MetS) in patients having 
atherosclerotic vascular disease. 
Methods: In this  cross sectional study 100 patients 
with atherosclerotic vascular disease were included. 
Patients were enquired about the presence of 
diabetes, hypertension, ischemic heart disease, 
symptoms of peripheral vascular disease and any 
history of ischemic stroke. Blood pressure and waist 
circumference were measured. Fasting blood sugar 
and lipid profile (triglyceride and HDL) were 
estimated.   
Results: The mean age of the patients was 
53.97±9.95 years. Forty five percent were males.  
Seventy five percent  presented with a history of 
ischemic heart disease, 19% presented with a history 
of ischemic stroke and 6% had peripheral vascular 
disease. Overall, 46% patients had metabolic 
syndrome. The mean age of the patients with MetS 
was significantly lower than the patients without 
MetS(p= 0.005). Among the 75 CAD patients 32 
(42.7%) had MetS; among the 19 ischemic stroke 
patients 10 (52.6%) had MetS and among the 6 PVD 
patients 4 (66.7%) had MetS. This difference in the 
proportion of patients with MetS was not 
statistically significant(p=0.427).  
Conclusion: Nearly half of the patients with 
atherosclerotic vascular disease have metabolic 
syndrome.  
Key Words: Metabolic syndrome, Ischemic heart 
disease,Stroke,Peripheral vascular disease,Obesity, 
Diabetes, Mortality 
 
Introduction 
Metabolic syndrome is becoming increasingly 
common. In patients with manifest vascular disease 
presence of MetS is associated with advanced vascular 
damage. Among patients with atherosclerotic vascular 
disease, those with MetS are at increased risk of 
subsequent vascular events as compared with those 
without. Metabolic syndrome patients are at increased 
risk for developing cardiovascular morbidity and 
mortality. The increasing prevalence of the metabolic 
syndrome in various asymptomatic populations has 
been well documented.Metabolic syndrome 
(Syndrome X, Insulin resistance syndrome) is a 
combination of medical disorders that increase the risk 
of developing type 2 diabetes and atherosclerotic 
vascular disease (ischemic heart disease, ischemic 
stroke, and peripheral vascular disease). 1 The major 
features of metabolic syndrome include central 
obesity, hypertriglyceridaemia, low HDL, 
hyperglycemia and hypertension.² Increase in waist 
circumference predominates in women whereas 
higher fasting triglyceride levels are more likely in 
men. Central obesity is a key feature of the syndrome, 
reflecting the fact that the syndrome’s prevalence is 
driven by the strong relationship between waist 
circumference and increasing adiposity.³ Despite the 
importance of obesity patients who are normal weight 
may also be insulin resistant and have the syndrome.. ⁴ 
Metabolic syndrome incidence increases with age. ⁵ 
MetS increases two-fold risk of mortality in patients 
with ischemic heart disease.6,7 With appropriate 
cardiac rehabilitation and changes in lifestyle the 
prevalence of the syndrome can be reduced. Patient 
with MetS are also at increased risk for ischemic stroke 
and peripheral vascular disease.8,9 Various strategies 
have been proposed to prevent the development of 
MetS. These include increase physical activity such as 
walking 30 minutes daily and a healthy, reduce calorie 
diet. However, drug treatment is frequently required 
to treat insulin resistance, hypertension and 
hyperlipidaemia.10   
Patients and Methods  
In this  cross sectional study, performed in Department 
of Medicine Benazir Bhutto Hospital, Rawalpindi,  100 
patients with atherosclerotic vascular disease were 
included .The study was carried out over 6 months 
from Oct 2012 to March 2013. Patients of all ages and 
both sexes having either ischemic heart disease or 
ischemic stroke or peripheral vascular disease were 
included. Patients with any cardiac  or vascular 
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disease due to vasculitis syndromes and patients 
having haemorrhagic stroke as evident by hyperdense 
area on CT scan, were excluded.Patients were 
enquired about the presence of diabetes, hypertension, 
symptoms of ischemic heart disease, symptoms of 
peripheral vascular disease and any history of 
ischemic stroke. Fasting blood sugar levels and lipid 
profile were done.  
The US national cholesterol education program adult 
treatment panel III (NCEP: ATP III criteria )was used 
to assess MetS. It  requires at least three out of  five 
(Table 1). BP Was measured in sitting position after 5 
minute rest as an average of    two readings taken 5 
minute apart. Waist circumference was calculated as 
an average of two measurements taken after 
inspiration and expiration at midpoint of lowest rib 
and iliac crest. Diagnosis of ischemic heart disease was 
established when patient  had history of  angina (chest 
pain on exertion, relieved by rest and nitrates),acute 
coronary syndrome(chest pain at rest, worsening chest 
pain , not relieved by nitrates with raised cardiac 
enzymes),ETT   positive   for  ischemia  (patient suffers 
isoelectric line or 1mm elevation in limb leads or 2mm 
elevation in chest leads). 
 
Table 1: NCEP: ATP III criteria of metabolic 
syndrome 
  Clinical measure  ATP III 
Waist Circumference ≥102 cm in men,  
≥88 cm in women 
Triglycerides ≥150 mg/dL 
HDL <40 mg/dL in men,  
<50 mg/dL in women 
Blood Pressure ≥130/85 mm Hg 
Glucose Fasting >110 mg/dL  
 
from chest pain during ETT or there are ischemic 
changes on ECG) and typical ischemic changes on 
ECG(T wave inversion,ST segment depression from 
Peripheral vascular disease was established on the 
basis of palpable vessels,feeble or absent pulse 
(Doppler showing biphasic or monophasic waveform) 
and having symptoms like intermittent claudication 
(leg pain on walking after a relatively constant 
distance and relieved by rest).Patients having history 
of   focal neurological deficit with or without recovery 
due to ischemic infarct (evident as hypodense area on 
CT scan) were diagnosed as a case of ischemic stroke . 
Results 
The age of the patients ranged from 35 to 79 years. The 
mean age was 53.97±9.95 years(Table 2). 45 were males 
and 55 were females.  Majority (75%) presented with a 
history of ischemic heart disease, 19 (19%) presented 
with a history of ischemic stroke and 6(6%) had 
peripheral vascular disease. Overall, 46% patients had 
metabolic syndrome. The mean age of the patients 
with metabolic syndrome was 51±9.05 year whereas 
the mean age of the patients without metabolic 
syndrome was 56.5±10.06 year; hence patients with 
MetS were significantly younger(p= 0.005).Among the 
45 males 17 (37.77%) had MetS, while among the 55 
females 29 (52.72%) had MetS. Although greater 
proportion of female patients had MetS this was not 
statistically significant(p= 0.136). Among the 75 CAD 
patients 32 (42.7%) had MetS; among the 19 ischemic 
stroke patients 10 (52.6%) had MetS and among the 6 
PVD patients 4 (66.7%) had MetS. This difference in 
the proportion of patients with MetS was not 
statistically significant(p=0.427).Fifty five percent 
patients had diabetes (Table 3). Twenty percent had 
one component, 34 (34%) had two component, 23 
(23%) had three components, 14 (14%) had four 
components and 9 (9%) had all five components. 
Among 75 patients with CAD 18 (24%) had one 
component, 25 (33%) had two component, 15 (20%) 
had three components, 10 (13.3%) had four 
components and 7 (9.3%) had all five components. 
Among 6 patients with PVD 2 (33.3%) had two 
component, 2 (33.3%) had three components and 2 
(33.3%) had all five components (Table 4). 
 
Table   1– Age distribution of patients in study 
group 
Age distribution Count 
30-39 yrs 8 
40-49 yrs 32 
50-59 yrs 38 
60-69 yrs 17 
70-89 yrs 6 
 
Table 3 – Various components of metabolic 
syndrome. 
Components  %age 
Diabetes 55% 
Hypertension 45% 
Increased Waist circumference 58% 
Abnormal HDL 48% 
Abnormal TG 52% 
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Table 3- Components of metabolic syndrome 
among  atherosclerotic vascular diseases 
 1 
(Diabetes) 
2 
(Hyper-
tension) 
3 
(Increased 
waist 
circumfe-
rence) 
4 
(Abnormal 
 HDL) 
5 
(Abnormal 
triglycerides) 
CAD 24.0 33.30 20.0 13.0 9.30 
Stroke 10.50 36.80 31.60 21.10 0 
PVD 0 33.30 33.30 0 33.3 
Total 34.50 103.4 84.9 34.1 42.6 
 
Discussion 
Risk factors, comprising metabolic syndrome, cause or 
accelerate atherosclerosis. In patients with the MetS a 
two- to three-fold increased risk of coronary heart 
disease (CHD) and stroke and cardiovascular 
mortality has been reported.11,¹²  Reported prevalence 
of the MetS in healthy subjects vary between 9 and 
22%.¹³ Drug-treated hypertensive patients revealed a 
prevalence varying from 0.8 to 35.3%. 14,15  Screening 
for MetS in an already high-risk population may help 
to identify patients with even higher risks for vascular 
complications and may direct therapy. Studies 
revealed hypertension and obesity as the main 
determinant.16-18  Screening for metabolic syndrome in 
patients with high risk for new vascular incidents may 
identify patients with even higher vascular risk and 
may direct anti-atherosclerotic treatment in order to 
prevent new vascular incidents in the same or another 
vascular bed. In a study by Yasmin et al  frequency of 
MetS was 32% in men and 28% in women. 19 Sandhu et 
al found the frequency of metabolic syndrome in 690 
patients presenting with acute myocardial infarction 
(MI) to be 40% among males and 44% among females. 
20 At Armed Forces Institute of Cardiology and 
National Institute of Heart Diseases, Rawalpindi Bhalli 
et al found that among 135 CAD patients metabolic 
syndrome (MS) was present in 55 (40.7%) patients. 21 
 MetS  is a combination of metabolic  disorders 
including known risk factors like dyslipidemia, 
hyperglycaemia and hypertension, but also risk factors 
not routinely measured like hyperinsulinemia, 
decreased fibrinolysis, oxidative stress, small dense 
LDL-cholesterol and increased inflammation.²² Instead 
of treating individual components of the metabolic 
syndrome, treating the underlying pathophysiological 
disturbance would ideally be the therapeutic option of 
first choice.  23,24 WHO and ATP III criteria gave 
similar prevalences of the metabolic syndrome in the 
Third National Health and Nutrition Examination 
Survey: 25.1% and 23.9%, respectively; 86.2% were 
classified the same under the two approaches. 20,25,26  In 
a study by Trevisan et al. in patients aged 50 or above, 
women had a higher prevalence than men. 27 A study 
in US adults showed that the prevalence of the MetS  
differed little among men and women in the general 
population (24% versus 23%), but after 70 years of age 
women had a higher prevalence. 27 
In the Botnia study, patients with the MetS and 
microalbuminuria were at markedly increased risk for 
cardiovascular death (relative risk 2.8) compared to 
patients with the MetS  but without microalbuminuria. 
Microalbuminuria is thought to be a surrogate for 
endothelial dysfunction and is an early marker for 
increased cardiovascular risk. 28 This may indicate that 
patients with the MetS and vascular damage or 
vascular dysfunction are at increased risk compared to 
patients with the MetS  but without vascular damage.  
Wassink et al conducted a prospective study of 3196 
patients with a history or recent diagnosis of clinically 
manifest vascular disease. 
 During a median follow-up of 3.2 years (interquartile 
range 1.4–5.4 years), 331 patients died and 373 patients 
experienced a first vascular event. 29 Jobien et al 
investigated whether the metabolic syndrome is 
related to the extent of vascular damage in patients 
with various manifestations of vascular disease.  The 
study population of this cross-sectional survey 
consisted of 502 patients recently diagnosed with 
coronary heart disease, 236 with stroke, 218 with 
peripheral arterial disease and 89 with abdominal 
aortic aneurysm. 30 MetS was diagnosed according to 
Adult Treatment Panel III criteria. Carotid Intima 
Media Thickness , Ankle Brachial Pressure Index and 
albuminuria were used as non-invasive markers of 
vascular damage and adjusted for age and sex if 
appropriate. The prevalence of the metabolic 
syndrome in the study population was 45%. 30,³¹ 
 
Conclusion 
1. There is a high prevalence of the metabolic 
syndrome in patients with  atherosclerotic 
vascular disease.   
2. Screening for metabolic syndrome in patients with 
high-risk for new vascular incidents may identify 
patients with even higher vascular risk and may 
direct anti-atherosclerotic treatment . 
3. The individual components that make up the 
syndrome should be treated coherently, with 
awareness of the underlying disorder. 
4. Newly developed drugs such as the peroxisome 
proliferator-activated receptor (PPAR) agonists 
may help to reach targets, along with life style 
modifications 
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